VistaGen Therapeutics, Inc. (VTGN) financial statements (2020 and earlier)

Company profile

Business Address 343 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. NV
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11310300 
Cash and cash equivalents11310300 
Receivables 0     
Prepaid expense0000000
Other undisclosed current assets 0100  
Total current assets:114113100
Noncurrent Assets
Operating lease, right-of-use asset4
Property, plant and equipment0000000
Other noncurrent assets0    00
Other undisclosed noncurrent assets 0000  
Total noncurrent assets:4000000
TOTAL ASSETS:514114100
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3311243
Accounts payable2111122
Accrued liabilities1200111
Employee-related liabilities     1 
Debt0000041
Due to related parties      0
Other undisclosed current liabilities0    91
Total current liabilities:33112175
Noncurrent Liabilities
Long-term debt and lease obligation4000000
Long-term debt, excluding current maturities    0  
Capital lease obligations000 00
Operating lease, liability4
Liabilities, other than long-term debt 000033
Deferred revenue and credits000  
Accounts payable and accrued liabilities     33
Deferred rent credit 0
Other undisclosed noncurrent liabilities5432205
Total noncurrent liabilities:8432238
Total liabilities:1174342113
Stockholders' equity
Stockholders' equity attributable to parent, including:(6)771(3)(21)(13)
Preferred stock     00
Common stock0000000
Treasury stock, value(4)(4)(4)(4)(4)(4)(4)
Additional paid in capital1961921671471336862
Accumulated deficit(199)(181)(157)(142)(132)(85)(71)
Other undisclosed stockholders' equity attributable to parent00000 (0)
Total stockholders' equity:(6)771(3)(21)(13)
TOTAL LIABILITIES AND EQUITY:514114100

Income statement (P&L) ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
Revenue, net 1   
Gross profit:   1   
Operating expenses(23)(25)(14)(11)(18)(7)(5)
Other undisclosed operating income     0 
Operating loss:(23)(25)(14)(10)(18)(7)(5)
Nonoperating income    0  
Foreign currency transaction gain, before tax    0  
Other nonoperating expense    (0)  
Interest and debt expense0(0)(0)(0)(27)(7)2
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes0   (2)(0)1
Loss from continuing operations before income taxes:(23)(25)(14)(10)(47)(14)(3)
Income tax expense(0)(0)(0)(0)(0)(0)(0)
Net loss attributable to parent:(23)(25)(14)(10)(47)(14)(3)
Preferred stock dividends and other adjustments(1)      
Other undisclosed net loss available to common stockholders, basic(0)(1)(1)(1)(4)  
Net loss available to common stockholders, basic:(24)(26)(16)(12)(51)(14)(3)
Other undisclosed net loss available to common stockholders, diluted     (0)(1)
Net loss available to common stockholders, diluted:(24)(26)(16)(12)(51)(14)(4)

Comprehensive Income ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
Net loss:(23)(25)(14)(10)(47)(14)(3)
Comprehensive loss, net of tax, attributable to parent:(23)(25)(14)(10)(47)(14)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: